Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6QN14
UPID:
U17L6_HUMAN
Alternative names:
Deubiquitinating enzyme 17-like protein 6; Ubiquitin thioesterase 17-like protein 6; Ubiquitin-specific-processing protease 17-like protein 6
Alternative UPACC:
Q6QN14
Background:
Ubiquitin carboxyl-terminal hydrolase 17-like protein 6, also known as Deubiquitinating enzyme 17-like protein 6, plays a crucial role in cellular processes by removing conjugated ubiquitin from specific proteins. This action regulates cell proliferation, cell cycle progression, cell migration, and the cellular response to viral infection.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 17-like protein 6 could open doors to potential therapeutic strategies.